CY1116681T1 - 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης - Google Patents
5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησηςInfo
- Publication number
- CY1116681T1 CY1116681T1 CY20151100786T CY151100786T CY1116681T1 CY 1116681 T1 CY1116681 T1 CY 1116681T1 CY 20151100786 T CY20151100786 T CY 20151100786T CY 151100786 T CY151100786 T CY 151100786T CY 1116681 T1 CY1116681 T1 CY 1116681T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- imidazopyridines
- relates
- anilinoimimaza
- pyridines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Devices For Indicating Variable Information By Combining Individual Elements (AREA)
Abstract
Η εφεύρεση σχετίζεται με ιμιδαζοπυριδίνες του τύπου 1 με αντικαρκινική και/ή αντιφλεγμονώδη δραστικότητα και ειδικότερα με ιμιδαζοπυριδίνες που αναστέλλουν την δραστικότητα κινάσης ΜΕΚ. Η εφεύρεση παρέχει συνθέσεις και μεθόδους που είναι χρήσιμες για αναστολή ανώμαλης κυτταρικής αύξησης ή για θεραπευτική αγωγή υπερπλαστικής διαταραχής, ή για θεραπευτική αγωγή φλεγμονώδους ασθένειας σε θηλαστικό. Η εφεύρεση σχετίζεται επίσης με μεθόδους χρήσης των ενώσεων για in vitro, in situ, και in vivo διάγνωση ή θεραπευτική αγωγή κυττάρων θηλαστικού, ή σχετιζόμενων παθολογικών καταστάσεων.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1512907P | 2007-12-19 | 2007-12-19 | |
| US5401408P | 2008-05-16 | 2008-05-16 | |
| EP13155995.7A EP2690101B1 (en) | 2007-12-19 | 2008-12-18 | 5-Anilinoimidazopyridines and Methods of Use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116681T1 true CY1116681T1 (el) | 2017-03-15 |
Family
ID=40350172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131101033T CY1114663T1 (el) | 2007-12-19 | 2013-11-21 | 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης |
| CY20151100786T CY1116681T1 (el) | 2007-12-19 | 2015-09-11 | 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131101033T CY1114663T1 (el) | 2007-12-19 | 2013-11-21 | 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US7923456B2 (el) |
| EP (2) | EP2690101B1 (el) |
| JP (1) | JP5421925B2 (el) |
| KR (1) | KR101195329B1 (el) |
| CN (1) | CN101945870B (el) |
| AR (1) | AR069803A1 (el) |
| AU (1) | AU2008343065B2 (el) |
| BR (1) | BRPI0819529A2 (el) |
| CA (1) | CA2706571C (el) |
| CL (1) | CL2008003810A1 (el) |
| CY (2) | CY1114663T1 (el) |
| DK (2) | DK2222675T3 (el) |
| ES (2) | ES2546171T3 (el) |
| HK (2) | HK1188209A1 (el) |
| HR (1) | HRP20151002T1 (el) |
| HU (1) | HUE025192T2 (el) |
| IL (1) | IL205977A (el) |
| MX (1) | MX2010006800A (el) |
| MY (1) | MY158829A (el) |
| NZ (1) | NZ586802A (el) |
| PE (2) | PE20131210A1 (el) |
| PL (2) | PL2222675T3 (el) |
| PT (2) | PT2222675E (el) |
| RU (1) | RU2441004C1 (el) |
| SI (2) | SI2690101T1 (el) |
| TW (1) | TWI441820B (el) |
| WO (1) | WO2009085983A1 (el) |
| ZA (1) | ZA201003625B (el) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2693997C (en) | 2007-08-03 | 2013-01-15 | Pierre L. Beaulieu | Viral polymerase inhibitors |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| US8343977B2 (en) | 2009-12-30 | 2013-01-01 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
| US8329705B2 (en) | 2009-12-30 | 2012-12-11 | Arqule, Inc. | Substituted triazolo-pyrazine compounds |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| CN103842030B (zh) | 2011-08-01 | 2018-07-31 | 霍夫曼-拉罗奇有限公司 | 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法 |
| WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
| CN109939236A (zh) | 2012-06-08 | 2019-06-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
| KR20150127203A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| GB201321729D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| AU2015206603B9 (en) | 2014-01-14 | 2019-07-18 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CR20160425A (es) | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
| PL3169361T3 (pl) | 2014-07-15 | 2019-11-29 | Hoffmann La Roche | Kompozycje do leczenia nowotworu z użyciem związków antagonistycznych wiązania osi pd-1 i inhibitorów mek |
| CN108358939A (zh) * | 2014-07-29 | 2018-08-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途 |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| ES2774448T3 (es) | 2014-10-03 | 2020-07-21 | Novartis Ag | Terapias de combinación |
| WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| ES2952717T3 (es) | 2014-10-14 | 2023-11-03 | Novartis Ag | Moléculas de anticuerpos contra PD-L1 y usos de las mismas |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| CA3004117A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| CN105399661A (zh) * | 2015-12-14 | 2016-03-16 | 华东师范大学 | 2,6-二溴甲基吡啶的制备方法 |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3458455B1 (en) | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| EP3484885B1 (en) | 2016-07-14 | 2020-03-04 | H. Hoffnabb-La Roche Ag | Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| WO2018011160A1 (en) * | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| CN109476668B (zh) * | 2016-07-14 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-三唑并[1,5-a]吡嗪化合物 |
| EP3484883B1 (en) | 2016-07-14 | 2020-04-15 | H. Hoffnabb-La Roche Ag | Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases |
| EP3505517A4 (en) * | 2016-08-23 | 2020-01-15 | Beijing InnoCare Pharma Tech Co., Ltd. | FUSED HETEROCYCLIC DERIVATIVE, ITS PREPARATION METHOD AND ITS MEDICAL USE |
| JP7530829B2 (ja) | 2017-09-08 | 2024-08-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの診断及び治療方法 |
| CA3081602A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| MX2020012598A (es) | 2018-05-24 | 2021-05-27 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos. |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US11572344B2 (en) * | 2018-11-20 | 2023-02-07 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3924054A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| AU2020259404A1 (en) | 2019-04-19 | 2021-09-23 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- PSMA/CD3 antibody |
| WO2020221811A1 (en) * | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| WO2021123902A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| KR20230137393A (ko) | 2021-01-28 | 2023-10-04 | 얀센 바이오테크 인코포레이티드 | Psma 결합 단백질 및 이의 용도 |
| US20240182464A1 (en) | 2021-02-02 | 2024-06-06 | Les Laboratoirens Serviece | Selective bcl-xl protac compounds and methods of use |
| WO2022195551A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU11248A1 (ru) | 1927-03-29 | 1929-09-30 | В.С. Григорьев | Способ очистки антрацена |
| ZA711710B (en) * | 1970-05-28 | 1971-12-29 | Squibb & Sons Inc | Amino derivatives of purazolo-pyridine carboxylic acids and esters |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| DK0591528T3 (da) * | 1991-04-22 | 1999-08-23 | Otsuka Pharma Co Ltd | Pyrazolo[1,5-a]pyrimidinderivat og antiinflammatorisk middel, der indeholder dette |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Ｐｉ３キナーゼ阻害剤とその製造法 |
| JPH08176070A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | ジデプシド誘導体及びｐｉ３キナーゼ阻害剤 |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| ATE198326T1 (de) | 1995-04-20 | 2001-01-15 | Pfizer | Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf |
| GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
| ATE237596T1 (de) | 1996-02-13 | 2003-05-15 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| YU1899A (sh) | 1996-07-18 | 2000-03-21 | Pfizer Inc. | Inhibitori matričnih metaloproteaza na bazi fosfinata |
| IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ES2224277T3 (es) | 1997-01-06 | 2005-03-01 | Pfizer Inc. | Derivados de sulfonas ciclicas. |
| KR100317146B1 (ko) | 1997-02-03 | 2001-12-22 | 데이비드 존 우드 | 아릴술포닐아미노 히드록삼산 유도체 |
| EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| KR20000070923A (ko) | 1997-02-11 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐 하이드록삼산 유도체 |
| DK0961780T3 (da) | 1997-02-12 | 2007-08-27 | Electrophoretics Ltd | Proteinmarkörer for lungecancer og anvendelse deraf |
| YU1900A (sh) | 1997-08-08 | 2002-08-12 | Pfizer Products Inc. | Derivati ariloksiarilsulfonilamino hidroksaminske kiseline |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PT1004578E (pt) | 1998-11-05 | 2004-06-30 | Pfizer Prod Inc | Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico |
| SK9832001A3 (en) * | 1999-01-13 | 2003-02-04 | Warner Lambert Co | Benzoheterocycles and their use as MEK inhibitors |
| CZ303692B6 (cs) | 1999-02-10 | 2013-03-13 | Astrazeneca Ab | Chinazolinové deriváty jako inhibitory angiogeneze |
| EP1202731A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
| EE05330B1 (et) | 1999-11-05 | 2010-08-16 | Astrazeneca Ab | Kinasoliini derivaadid kui VEGF-i inhibiitorid |
| US6420365B1 (en) * | 2000-01-18 | 2002-07-16 | Neurogen Corporation | Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors |
| CZ303705B6 (cs) | 2000-02-15 | 2013-03-27 | Sugen, Inc. | Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem |
| JP2001247477A (ja) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | 抗腫瘍剤 |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| FR2811987A1 (fr) | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
| JP5079202B2 (ja) | 2000-07-18 | 2012-11-21 | 大日本住友製薬株式会社 | セロトニン再取り込み阻害剤 |
| EE05450B1 (et) * | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
| EP1417976A4 (en) | 2001-07-26 | 2004-09-15 | Santen Pharmaceutical Co Ltd | AGENT FOR TREATING GLAUKOM WITH A COMPOUND WITH PI3-KINASE INHIBITING EFFECT |
| US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
| AU2002349912A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| US6894055B2 (en) | 2001-10-24 | 2005-05-17 | Iconix Pharmaceuticals Inc. | Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase |
| WO2003037886A2 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| WO2003068773A1 (en) | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| DE60330227D1 (de) | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| TW200406203A (en) * | 2002-03-13 | 2004-05-01 | Array Biopharma Inc | N3 alkylated banzimidazole derivatives as MEK inhibitors |
| CN1681811B (zh) | 2002-07-10 | 2010-05-26 | 默克雪兰诺有限公司 | 唑烷酮-乙烯基稠合的-苯衍生物 |
| US20050222225A1 (en) | 2002-07-10 | 2005-10-06 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility |
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| AU2003295332B2 (en) * | 2002-09-19 | 2007-01-18 | Merck Sharp & Dohme Corp. | Imidazopyridines as cyclin dependent kinase inhibitors |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN1905873A (zh) * | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| ATE443063T1 (de) * | 2004-12-01 | 2009-10-15 | Merck Serono Sa | Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| CA2671782C (en) | 2006-12-07 | 2017-01-10 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| AU2008343062B2 (en) * | 2007-12-19 | 2013-03-07 | Genentech, Inc. | 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
-
2008
- 2008-12-18 SI SI200831490T patent/SI2690101T1/sl unknown
- 2008-12-18 PE PE2013000381A patent/PE20131210A1/es not_active Application Discontinuation
- 2008-12-18 NZ NZ586802A patent/NZ586802A/en not_active IP Right Cessation
- 2008-12-18 RU RU2010129826/04A patent/RU2441004C1/ru not_active IP Right Cessation
- 2008-12-18 CA CA2706571A patent/CA2706571C/en not_active Expired - Fee Related
- 2008-12-18 AR ARP080105524A patent/AR069803A1/es unknown
- 2008-12-18 PT PT88691001T patent/PT2222675E/pt unknown
- 2008-12-18 EP EP13155995.7A patent/EP2690101B1/en active Active
- 2008-12-18 PL PL08869100T patent/PL2222675T3/pl unknown
- 2008-12-18 CN CN2008801270848A patent/CN101945870B/zh active Active
- 2008-12-18 SI SI200831088T patent/SI2222675T1/sl unknown
- 2008-12-18 KR KR1020107015884A patent/KR101195329B1/ko not_active IP Right Cessation
- 2008-12-18 CL CL2008003810A patent/CL2008003810A1/es unknown
- 2008-12-18 DK DK08869100.1T patent/DK2222675T3/da active
- 2008-12-18 HU HUE13155995A patent/HUE025192T2/en unknown
- 2008-12-18 AU AU2008343065A patent/AU2008343065B2/en not_active Ceased
- 2008-12-18 PT PT131559957T patent/PT2690101E/pt unknown
- 2008-12-18 PE PE2008002130A patent/PE20091158A1/es not_active Application Discontinuation
- 2008-12-18 WO PCT/US2008/087482 patent/WO2009085983A1/en active Application Filing
- 2008-12-18 ES ES13155995.7T patent/ES2546171T3/es active Active
- 2008-12-18 MY MYPI2010002814A patent/MY158829A/en unknown
- 2008-12-18 EP EP08869100.1A patent/EP2222675B1/en active Active
- 2008-12-18 PL PL13155995T patent/PL2690101T3/pl unknown
- 2008-12-18 JP JP2010539815A patent/JP5421925B2/ja active Active
- 2008-12-18 ES ES08869100.1T patent/ES2437141T3/es active Active
- 2008-12-18 MX MX2010006800A patent/MX2010006800A/es active IP Right Grant
- 2008-12-18 BR BRPI0819529-3A patent/BRPI0819529A2/pt not_active IP Right Cessation
- 2008-12-18 DK DK13155995.7T patent/DK2690101T3/en active
- 2008-12-18 TW TW097149416A patent/TWI441820B/zh not_active IP Right Cessation
-
2009
- 2009-04-29 US US12/432,529 patent/US7923456B2/en active Active
-
2010
- 2010-05-21 ZA ZA2010/03625A patent/ZA201003625B/en unknown
- 2010-05-26 IL IL205977A patent/IL205977A/en not_active IP Right Cessation
-
2011
- 2011-02-10 HK HK14101128.7A patent/HK1188209A1/xx unknown
- 2011-02-10 HK HK11101302.8A patent/HK1147254A1/xx unknown
- 2011-03-07 US US13/041,735 patent/US8288408B2/en active Active
-
2012
- 2012-08-15 US US13/586,147 patent/US20120309765A1/en not_active Abandoned
-
2013
- 2013-02-05 US US13/759,850 patent/US9206174B2/en active Active
- 2013-11-21 CY CY20131101033T patent/CY1114663T1/el unknown
-
2015
- 2015-09-11 CY CY20151100786T patent/CY1116681T1/el unknown
- 2015-09-23 HR HRP20151002TT patent/HRP20151002T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116681T1 (el) | 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης | |
| ATE513832T1 (de) | 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel | |
| CY1116692T1 (el) | Πυρρολοπυριδινες ως αναστολεις κινασης | |
| WO2010003022A8 (en) | Isoindolone derivatives as mek kinase inhibitors and methods of use | |
| ECSP10010507A (es) | Pirazolo (3, 4-b) piridina inhibidores de raf | |
| WO2008157179A3 (en) | N-substituted azaindoles and methods of use | |
| NO20091197L (no) | Azabenzofuranylforbindelser og anvendelser derav | |
| CY1126122T1 (el) | Αναστολεις πρωτεϊνικης φωσφατασης της τυροσινης | |
| CY1124148T1 (el) | Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο | |
| CO6950483A2 (es) | 5,7-imidazo[1,2-c]pirimidinas sustituidas | |
| EA201390879A1 (ru) | Трициклические ингибиторы pi3k и способы их применения | |
| MY160349A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| MX2014005282A (es) | Compuestos de 8-fluoroftalazin-1 (2h) -ona. | |
| CY1118438T1 (el) | Αναλογα τριαζινης, πυριμιδινης και πυριδινης και η χρηση τους ως θεραπευτικοι παραγοντες και διαγνωστικοι ανιχνευτες | |
| MX2014005289A (es) | Compuestos de piperazina alquilados. | |
| MX2014005331A (es) | Compuestos de heteroaril piridona y aza-piridona. | |
| GT201200242A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| MX2014014828A (es) | Compuestos de 5-azaindazol y metodos de uso. | |
| CO6620050A2 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| CU24269B1 (es) | 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante | |
| SG178899A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| CR10338A (es) | Compuestos pirazolicos heterobiciclicos y metodos de uso | |
| MX2014005285A (es) | Compuestos biciclicos de piperazina. | |
| MX2014001239A (es) | Compuestos de pirazolo [3,4-c] piridina y metodos de uso. | |
| ECSP109953A (es) | Derivados de piridazinona |